Patents by Inventor Guy DiPierro

Guy DiPierro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11920156
    Abstract: The present invention provides engineered Natural Killer (NK) cells and methods of producing engineered NK cells. The engineered NK cells and compositions containing the engineered NK cells are useful for treating diseases such as cancer.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: March 5, 2024
    Assignee: Indapta Therapeutics, Inc.
    Inventor: Guy Dipierro
  • Publication number: 20230277767
    Abstract: Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agent delivery device. Bio-synchronous drug delivery includes continual collection of patient data such as physical, psychological, temporal and environmental characteristics. This data is analyzed so to not only determine an initial treatment protocol but to also determining whether modification to the ongoing bio-synchronous treatment protocol is required. And, responsive to determining a modification is required the system modifies the bio-synchronous treatment protocol and use of delivery device. These modifications and treatment protocols can include reactive and proactive psychological support supplied to the patient in a variety of formats.
    Type: Application
    Filed: September 29, 2022
    Publication date: September 7, 2023
    Inventors: Guy DiPIERRO, Alan Joel LEVY
  • Publication number: 20230190801
    Abstract: Provided herein are methods for ex vivo expansion of a specialized subset of natural killer (NK) cells, and compositions containing such NK cells. Also provided are methods for identifying or detecting a specialized subset of NK cells. Also provided are methods for treating diseases and conditions such as cancer using provided compositions, including in combination with an antibody capable of binding to disease-associated tissues or cells, such as tumor cells or infected cells.
    Type: Application
    Filed: April 21, 2021
    Publication date: June 22, 2023
    Applicant: Indapta Therapeutics, Inc.
    Inventors: Austin BIGLEY, Guy DIPIERRO
  • Patent number: 11471424
    Abstract: Systems and methods for synchronizing the administration of compounds with the human body's natural circadian rhythms and addiction rhythms to counteract symptoms when they are likely to be at their worst by using an automated and preprogrammable transdermal or other drug administration system.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: October 18, 2022
    Assignee: Morningside Venture Investments Limited
    Inventor: Guy DiPierro
  • Publication number: 20220008466
    Abstract: Provided herein are methods for ex vivo expansion of a specialized subset of natural killer (NK) cells, and compositions containing such NK cells. Also provided are methods for identifying or detecting a specialized subset of NK cells. Also provided are methods for treating diseases and conditions such as cancer using provided compositions, including in combination with an antibody capable of binding to disease-associated tissues or cells, such as tumor cells or infected cells.
    Type: Application
    Filed: November 21, 2019
    Publication date: January 13, 2022
    Applicant: Indapta Therapeutics, Inc
    Inventors: Austin BIGLEY, Ronald MARTELL, Guy DIPIERRO
  • Publication number: 20210187025
    Abstract: Provided herein are compositions containing specialized subsets of natural killer (NK) cells with enhanced antibody-directed immune responses. The compositions are useful for treating diseases and conditions such as cancer, including in combination with an antibody capable of binding to disease-associated tissues or cells, such as tumor cells or infected cells.
    Type: Application
    Filed: May 14, 2019
    Publication date: June 24, 2021
    Applicant: Indapta Therapeutics, Inc.
    Inventors: Guy DIPIERRO, Gary DOS SANTOS
  • Publication number: 20210169822
    Abstract: The invention concerns a transdermal delivery system for controlled dispensing of an active substance to and through a porous surface. A certain amount of fluid comprising at least one active substance and at least one solvent is dispensed into an administration reservoir. In the administration reservoir the at least one solvent is separated from the administration reservoir by a solvent recovery means such that the active substance achieves a certain level on an interface device which is permeable for the one active substance. Thereby the active substance is absorbable via diffusion from the interface device by a porous surface to be treated.
    Type: Application
    Filed: July 20, 2020
    Publication date: June 10, 2021
    Inventors: Werner ZUMBRUNN, Georgios IMANIDIS, Guy DiPIERRO, Hans Wernher VAN DE VENN
  • Publication number: 20200368175
    Abstract: A method of delivering nicotine to treat dyskinesia, such as Levodopa induced dyskinesia (LID), includes delivering a first dose of nicotine to a patient using a transdermal delivery device and delivering a second dose of nicotine to the patient using the transdermal delivery device. The first and second doses are timed such that a refractory period between peak plasma levels of nicotine in the patient prevents desensitization of nicotinic acetylcholine receptors while reducing symptoms of LID.
    Type: Application
    Filed: January 5, 2018
    Publication date: November 26, 2020
    Inventors: Anubhav ARORA, Navdeep KAUR, Guy DiPIERRO, Patrick H. RUANE, Ravinder D. PAMNANI
  • Publication number: 20200330369
    Abstract: Systems and methods for synchronizing the administration of compounds with the human body's natural circadian rhythms and addiction rhythms to counteract symptoms when they are likely to be at their worst by using an automated and preprogrammable transdermal or other drug administration system.
    Type: Application
    Filed: February 24, 2020
    Publication date: October 22, 2020
    Applicant: Morningside Venture Investments Limited
    Inventor: Guy DiPIERRO
  • Patent number: 10716764
    Abstract: The invention concerns a transdermal delivery system for controlled dispensing of an active substance to and through a porous surface. A certain amount of fluid comprising at least one active substance and at least one solvent is dispensed into an administration reservoir. In the administration reservoir the at least one solvent is separated from the administration reservoir by a solvent recovery means such that the active substance achieves a certain level on an interface device which is permeable for the one active substance. Thereby the active substance is absorbable via diffusion from the interface device by a porous surface to be treated.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: July 21, 2020
    Assignee: Morningside Venture Investments Limited
    Inventors: Werner Zumbrunn, Georgios Imanidis, Guy DiPierro, Hans Werner Van De Venn
  • Publication number: 20190376036
    Abstract: The present invention provides engineered Natural Killer (NK) cells and methods of producing engineered NK cells. The engineered NK cells and compositions containing the engineered NK cells are useful for treating diseases such as cancer.
    Type: Application
    Filed: February 8, 2018
    Publication date: December 12, 2019
    Applicant: Indapta Therapeutics, Inc.
    Inventor: Guy DIPIERRO
  • Patent number: 10258738
    Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, nutraceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: April 16, 2019
    Assignee: Chrono Therapeutics Inc.
    Inventors: Guy DiPierro, Steven A. Giannos
  • Patent number: 10258778
    Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, nutraceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: April 16, 2019
    Assignee: Chrono Therapeutics Inc.
    Inventors: Guy DiPierro, Steven A. Giannos
  • Publication number: 20190054235
    Abstract: Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agent delivery device. Bio-synchronous drug delivery includes continual collection of patient data such as physical, psychological, temporal and environmental characteristics. This data is analyzed so to not only determine an initial treatment protocol but to also determining whether modification to the ongoing bio-synchronous treatment protocol is required. And, responsive to determining a modification is required the system modifies the bio-synchronous treatment protocol and use of delivery device. These modifications and treatment protocols can include reactive and proactive psychological support supplied to the patient in a variety of formats.
    Type: Application
    Filed: October 19, 2018
    Publication date: February 21, 2019
    Inventors: Guy DiPIERRO, Alan Joel LEVY
  • Patent number: 10105487
    Abstract: Optimized bio-synchronous drug delivery begins with establishing a bio-synchronous treatment protocol that incorporates individual temporal and innate biological characteristics into a pharmacological treatment plan. The bio-synchronous treatment protocol is thereafter initiated using bioactive agent delivery device. Bio-synchronous drug delivery includes continual collection of patient data such as physical, psychological, temporal and environmental characteristics. This data is analyzed so to not only determine an initial treatment protocol but to also determining whether modification to the ongoing bio-synchronous treatment protocol is required. And, responsive to determining a modification is required the system modifies the bio-synchronous treatment protocol and use of delivery device. These modifications and treatment protocols can include reactive and proactive psychological support supplied to the patient in a variety of formats.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: October 23, 2018
    Assignee: CHRONO THERAPEUTICS INC.
    Inventors: Guy DiPierro, Alan Joel Levy
  • Publication number: 20170224911
    Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, nutraceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor.
    Type: Application
    Filed: April 21, 2017
    Publication date: August 10, 2017
    Inventors: Guy DIPIERRO, Steven A. GIANNOS
  • Publication number: 20170182299
    Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, nutraceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor.
    Type: Application
    Filed: March 14, 2017
    Publication date: June 29, 2017
    Inventors: Guy DIPIERRO, Steven A. GIANNOS
  • Patent number: 9669199
    Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: June 6, 2017
    Assignee: Chrono Therapeutics Inc.
    Inventors: Guy DiPierro, Steven A. Giannos
  • Publication number: 20170100572
    Abstract: The invention concerns a transdermal delivery system for controlled dispensing of an active substance to and through a porous surface. A certain amount of fluid comprising at least one active substance and at least one solvent is dispensed into an administration reservoir. In the administration reservoir the at least one solvent is separated from the administration reservoir by a solvent recovery means such that the active substance achieves a certain level on an interface device which is permeable for the one active substance. Thereby the active substance is absorbable via diffusion from the interface device by a porous surface to be treated.
    Type: Application
    Filed: December 20, 2016
    Publication date: April 13, 2017
    Inventors: Werner ZUMBRUNN, Georgios IMANIDIS, Guy DiPIERRO, Hans Werner VAN DE VENN
  • Publication number: 20170100573
    Abstract: Systems and methods for synchronizing the administration of compounds with the human body's natural circadian rhythms and addiction rhythms to counteract symptoms when they are likely to be at their worst by using an automated and preprogrammable transdermal or other drug administration system.
    Type: Application
    Filed: December 20, 2016
    Publication date: April 13, 2017
    Inventor: Guy DiPIERRO